What's new? Log in Free sign up

Home
Sectors & IndustriesSectors
Earnings
IPOs
Transcripts
Insider
Institutional
Splits

PHXM Dashboard
Financials
Filings
Holdings
Transcripts
ETFs
Insider
Institutional
Shorts
6-K Filing

PHAXIAM Therapeutics (PHXM) 6-KCurrent report (foreign)

Filed: 28 Jun 22, 9:01am

Free signup for more

Track your favorite companies
Receive email alerts for new filings
Personalized dashboard of news and more
Access all data and search results

Search this filing

All

Tables only

Footnotes only

Pre-defined:

Table of contents

Filing tables

Export all tables to Excel

Filing exhibits

6-K Current report (foreign)
99.1 EX-99.1

PHXM similar filings

12 Sep 22 I.Certification of the Person Responsible for the Half-year Financial Report
12 Sep 22 I.Certification of the Person Responsible for the Half-year Financial Report
25 Aug 22 ERYTECH Provides Regulatory Update
28 Jun 22 Current report (foreign)
25 May 22 Current report (foreign)
13 May 22 ERYTECH Provides Business and Financial Update for the First Quarter of 2022
2 May 22 ERYTECH Announces Filing of 2021 Universal Registration Document and 2021 Annual Report on Form 20-F, as well as its 2022 financial calendar

Filing view

Default size S M L
Default font Times Arial

External links

View on EDGAR (sec.gov)

Share this filing

UNITED STATES SECURITIES

AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________________

FORM 6-K

________________________

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of June 2022

Commission File Number: 001-38281

ERYTECH Pharma S.A.

(Translation of registrant’s name into English)

________________________

60 Avenue Rockefeller

69008 Lyon France

(Address of principal executive office)

________________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F S Form 40-F £

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): £

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): £

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

Press Release

On June 24, 2022, ERYTECH Pharma S.A. issued a press release announcing the voting results of its Annual General Meeting held on June 24, 2022.

A copy of this press release is attached to this Form 6-K as Exhibit 99.1.

EXHIBITS


Exhibit						Description

99.1						Press Release dated June 24, 2022.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ERYTECH Pharma S.A.

Date:

June 28, 2022

By:

/s/ Eric Soyer

Name Eric Soyer

Title: Chief Financial Officer and Chief Operating Officer

Resources

Knowledgebase
Log In
Register

Company

About
Contact
Solutions

Products

Deal Roadshow
DealVDR
Evercall
Finsight.com

CapEdge

Earnings Calendar
Earnings Transcripts
EDGAR Filing Screener
IPO Calendar

Compliance
Privacy
Security
Terms

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.